Observational studyAlzheimer's research & therapy2026
Association of circulating proteasome activity with Alzheimer's pathology and cognitive functions in APOE ε4 carriers.
Observational study in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- APOE4 disrupts the central dogma by arresting neuronal proteome dynamics.bioRxiv : the preprint server for biology · 2026Article
- Association between Alzheimer's disease and MHC-I antigen processing and presentation pathway: a narrative review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe proteasome is a major intracellular protease complex, but the significance of circulating proteasome activity in Alzheimer’s disease (AD) is not well established. Because APOE ε4 is the strongest genetic risk factor for AD, we examined whether plasma proteasome activity is associated with AD-related pathology, neurodegeneration, and cognitive decline, focusing on APOE ε4 carriers.
methodsIn this observational study, participants were classified as cognitively normal (CN), mild cognitive impairment (MCI), and dementia. All underwent 3.0-T MRI, [18F]flutemetamol PET for amyloid, [18F]MK-6240 PET for tau, APOE genotyping, and neuropsychological testing. Circulating proteasome activity was measured using fluorogenic substrates. Associations between proteasome activity and imaging or clinical features were assessed after stratifying by APOE ε4 status. Mediation analyses evaluated whether amyloid or tau burden indirectly linked proteasome activity with hippocampal volume or cognition.
resultsA total of 148 individuals were included (58 CN, 39 MCI, 38 AD dementia, and 13 other dementia). Significant associations appeared only in APOE ε4 carriers (n = 55). Higher proteasome activity was associated with lower amyloid burden (β = − 0.336, p = 0.009), lower global tau burden (β = − 0.268, p = 0.047), and reduced tau in Braak I/II (β = − 0.298, p = 0.033) and Braak III/IV regions (β = − 0.296, p = 0.033). Proteasome activity was positively associated with hippocampal volume (β = 0.374, p = 0.001) and with cognitive performance, including MMSE (β = 0.294, p = 0.026), CDR-SOB (β = − 0.365, p = 0.005). No significant associations were found in noncarriers. Mediation analyses showed that amyloid burden explained ~ 29% and Braak I/II tau ~ 23% of the proteasome–hippocampal volume relationship, while tau in Braak I/II and III/IV regions mediated 24–41% of the associations between proteasome activity and global cognition.
conclusionsDownregulated proteasome activity is strongly associated with amyloid burden, early tau accumulation, hippocampal atrophy, and cognitive impairment only in APOE ε4 carriers. These findings suggest that plasma proteasome activity may serve as a noninvasive marker of AD-related vulnerability in genetically at-risk individuals. Further studies are needed to clarify whether proteasome activity contributes to or results from amyloid and tau aggregation.
trial registrationKCT0005428. Registered September 24, 2020. Study subjects included in this analysis were those recruited from November 2018 onwards (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.